Lantern Pharma Inc.
NASDAQ:LTRNBiotechnology
-$0.19 today
- Market cap
- $50.14M
- Beta
- 2.32
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$1.41
Volume 0.10M
Average 0.68M
LTRN Operating Cash Flow
Cash generated by the company's core business operations during the period.
Lantern Pharma Inc.NASDAQ: LTRN
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow declines year over year
Q1 FY2026 operating cash flow of $3.77M (cash outflow) fell 13.8% year over year, ahead of the -21.2% change in trailing-twelve-month operating cash flow. Sequentially, it rose 35.1% from the prior quarter. Over 3 fiscal years it compounded at +7.1% a year.
Context
- Operating cash flow grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -13.8% holds above the trailing-twelve-month pace of -21.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (15.68M) USD
- Year-over-year change
- +12.0%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (15.68M) | +12.0% |
| FY2024 | 2024-12-31 | (17.81M) | -24.2% |
| FY2023 | 2023-12-31 | (14.35M) | -12.4% |
| FY2022 | 2022-12-31 | (12.77M) | -20.5% |
| FY2021 | 2021-12-31 | (10.59M) | — |
Operating Cash Flow vs competitors
How LTRN compares with its peers on the latest reported figures
- LTRN's LTM Mar 2026 operating cash flow of $15.07M is the 4th largest of the 5 companies compared; the peer median is $21.31M.
- Its year-over-year change of -21.2% is the 4th highest of 5, against a peer median of +12.6%.
- Over three fiscal years its annual growth of +7.1% compares with a peer median of +15.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $26.53M | +15.6% | +1039.6% | — | |
| LTM Jun 2026 | $22.66M | -26.2% | — | 64.6% | |
| LTM Mar 2026 | $19.95M | +22.3% | +15.9% | — | |
| LTM Mar 2026 | $15.07M | -21.2% | +7.1% | — | |
| LTM Mar 2026 | $11.3M | +9.7% | +7.6% | 759.0% | |
| Peer median (excluding LTRN) | $21.31M | +12.6% | +15.9% | 411.8% | |
Competitors are the stored peer set for LTRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.36M) | (14.26M) | (15.96M) | (20.78M) | (17.12M) |
| Depreciation & Amortization | 6.76K | 10.08K | 14.62K | 190.49K | 17.28K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 961.55K | 1.19M | 1.07M | 0 | 650.88K |
| Change in Working Capital | 599.96K | (611.86K) | 538.02K | 2.23M | 635.28K |
| Accounts Receivables | 0 | 0 | 0 | (175.72K) | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 1.64M | 0 |
| Other Working Capital | 599.96K | (611.86K) | 538.02K | 767.44K | 635.28K |
| Other Non-Cash Items | 203.22K | 906.49K | (5.17K) | 549.36K | 139.02K |
| Operating Cash Flow | (10.59M) | (12.77M) | (14.35M) | (17.81M) | (15.68M) |
| Capital Expenditures | (15.5K) | (27.84K) | (18.73K) | (12.6K) | (1.72K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (19.58M) | (3.91M) | (8.2M) | (17.28M) | (14.72M) |
| Sales of Investments | 64.09K | 4.12M | 7.28M | 20.66M | 25.78M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (19.53M) | 179.27K | (930.21K) | 3.37M | 11.06M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 69M | 0 | 0 | 66.71K | 1.64M |
| Common Stock Repurchased | 0 | (2.48M) | (500K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (4.64M) | 2.78M | 0 | 0 | (139.75K) |
| Financing Cash Flow | 63.42M | (2.18M) | (500K) | 66.71K | 1.5M |
| Effect of Forex Changes | 1.07K | (10.61K) | (28.46K) | (49.55K) | 33.43K |
| Net Change in Cash | 33.3M | (14.78M) | (15.81M) | (14.43M) | (3.09M) |
| Free Cash Flow | (10.61M) | (12.8M) | (14.37M) | (17.83M) | (15.68M) |
Lantern Pharma Inc.
NASDAQ:LTRN
Intrinsic Alpha fair value
Locked
Current Price
$3.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.